Paradigm Biopharmaceuticals Ltd has released a press release.
Paradigms preclinical hay fever trial published
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
In the deck
Earlier from Paradigm Biopharmaceuticals
- Paradigm Government grant for Ross River virus research
- Paradigm March Quarter Update & Appendix 4C
- Final participant treated in Phase 2 hay fever trial
- Paradigm receives $1.34 million R&D tax incentive rebate
- Paradigm Update Ross River Virus Clinical Trial
Later from Paradigm Biopharmaceuticals
- Paradigm Receives Ethics Approval for Ross River Trial
- Hay Fever Trial Update
- Paradigm Enters Heart Failure Market
- Paradigm To Commence Phase 2 Ross River Virus Clinical Trial
- Paradigm (PAR) - First Ross River Trial Participant Treated
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals